DAIICHI SANKYO CO LTD

EMA approves AstraZeneca‑Daiichi Sankyo’s Enhertu and Datroway ADCs—pioneering tumor‑agnostic HER2 therapy and first‑line TNBC treatment—shaping European oncology, pricing, and reimbursement strategies.

Explore how Daiichi Sankyo’s €1 billion investment in Germany boosts its EU market‑access, tackles patent cliffs, and fuels biologics innovation.

Discover how Daiichi Sankyo’s partnership with AstraZeneca on ADC Datroway is reshaping high‑margin oncology markets, driving $1.2 B annual sales and patient‑centric pricing.

DS’s ADC push—Ifinatamab Deruxtecan for SCLC and Raludotag for ovarian cancer—sets a new growth path, backed by Merck and 2030 sales targets.

Regulatory wins for AstraZeneca and Daiichi Sankyo—Enhertu, Datroway and camizestrant—signal a surge in tumour‑agnostic, ADC‑based oncology therapies that promise broader market reach and stronger value‑based pay‑for‑performance models.

Discover how Daiichi Sankyo’s strong oncology growth, AI‑driven ADC development, and smart market‑access tactics position it for a bullish future.

FDA reviews reveal pharma’s push to expand drug indications to earlier‑line and underserved patients, driving market share, pricing, and reimbursement shifts.

Discover how Daiichi Sankyo’s latest earnings forecast signals rising profits, expanding revenue, and strong pharma growth ahead of its April 2026 financial release.

Explore Daiichi Sankyo’s Q1 2026 earnings: 5.5 % revenue lift, 3.3 % EPS rise, and strategic gains amid Japan’s value‑based drug pricing.

Japanese equities climb as Japan’s mAb market expands – explore the drivers, regulatory updates, and clinical insights shaping the future of antibody therapies.